RBX2660 may bring an innovative therapeutic option to patients suffering from C. diff More: Rebiotix, Ferring's microbiome-based therapy RBX2660 shows promise Source: News
read moreThe approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option More: Speedy US approval for Novartis' Tabrecta Source: News
read moreAmgen is planning to file for FDA approval of Otezla in mild to moderate plaque psoriasis based on new data showing patients on the drug experienced significant improvements in their symptoms. The label expansion will be key to Amgen’s ability
read moreGerman drugmaker Fresenius Kabi has made major investments in its U.S. manufacturing operations in recent years with some mixed quality results along the way. Now, one of the drugmaker’s products faces a recall for more manufacturing woes. More: Fresenius Kabi
read moreNovo Nordisk’s popular GLP-1 injectable semaglutide—sold under the brand Ozempic as a weekly diabetes therapy—said Wednesday it had racked up encouraging mid-stage data in the hot new NASH field. Now, industry watchers are laying out their expectations for a phase
read moreAstraZeneca has watched superstar SGLT2 diabetes med Farxiga nail trial after trial in highly coveted kidney and heart failure indications, with the FDA expediting reviews to back them up. The one thing AstraZeneca was missing? The agency taking Farxiga across the
read more© 1994 - 2026 B.M. Pharmaceuticals